Tonix Pharmaceuticals Holding Corp. (TNXP)

4.65
0.17 3.62
NASDAQ : Health Technology
Prev Close 4.82
Open 4.85
Day Low/High 4.60 / 4.89
52 Wk Low/High 2.70 / 5.11
Volume 90.46K
Avg Volume 104.10K
Exchange NASDAQ
Shares Outstanding 8.46M
Market Cap 40.36M
EPS -3.20
P/E Ratio 1.34
Div & Yield N.A. (N.A)

Latest News

Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Patent Will Provide Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in the Treatment of Posttraumatic Stress Disorder (PTSD)

Tonix Pharmaceuticals Completes Positive Pre-IND Meeting With FDA For TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) As A Clinical Candidate For Agitation In Alzheimer's Disease

Tonix Pharmaceuticals Completes Positive Pre-IND Meeting With FDA For TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) As A Clinical Candidate For Agitation In Alzheimer's Disease

FDA Official Minutes Support Tonix's Plan to File an IND in First Quarter 2018 for a Phase 2 Study

Mirati Skyrockets On Positive Data - Biotech Movers

Mirati Skyrockets On Positive Data - Biotech Movers

The San Diego firm is scheduled to present positive preliminary data for two clinical studies of sitravatinib in non-small cell lung cancer at a symposium in Chicago on Friday.

Tonix Pharmaceuticals Receives European Patent For The Active Ingredient In Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Tonix Pharmaceuticals Receives European Patent For The Active Ingredient In Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Patent Will Provide Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in the Treatment of Posttraumatic Stress Disorder (PTSD)

Tonix Pharmaceuticals To Present Additional Phase 2 Clinical Results And Design Of Ongoing Phase 3 Trial In Military-Related PTSD At The 2017 Military Health System Research Symposium

Tonix Pharmaceuticals To Present Additional Phase 2 Clinical Results And Design Of Ongoing Phase 3 Trial In Military-Related PTSD At The 2017 Military Health System Research Symposium

Retrospective Analyses from Phase 2 Study of US FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) in PTSD will be Highlighted

Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Programs Update

Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Programs Update

Interim Analysis of Phase 3 HONOR study of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) in Military-Related PTSD Expected 1H18 and Topline Results Expected 2H18